SCHEMBL25754833

SCHEMBL25754833

CCc1ccc(N)cc1S(=O)(=O)Nc1ccc(Br)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.54
GAA P10253 1/20 0.49
EDNRA P25101 4/20 0.47
EDNRB P24530 3/20 0.47
MAPT P10636 6/20 0.45
NPSR1 Q6W5P4 2/20 0.45
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
TP53 P04637 1/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 3/20 0.43
USP2 O75604 2/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
HTR6 P50406 2/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754797 0.87 GAA (0.50) PKMGAAMAPTCA1CA2
SCHEMBL25754837 0.86 MAPT (0.58) GAAMAPTNPSR1TP53MEN1
SCHEMBL23846511 0.83 NHERF1 (0.49) PKMGAAMAPTTP53MEN1
SCHEMBL25754835 0.82 IDH1 (0.53) GAAMAPTCA1CA2MEN1
SCHEMBL25759435 0.82 GAA (0.43) PKMGAAMAPTNPSR1CA1
SCHEMBL23847021 0.79 PKM (0.56) PKMGAAMAPTNPSR1CA1
SCHEMBL17980891 0.79 MAPT (0.60) PKMGAAMAPTMEN1KMT2A
SCHEMBL25754703 0.79 CYP19A1 (0.44) PKMEDNRAEDNRBMAPTCA1
SCHEMBL25754798 0.78 EDNRA (0.47) GAAEDNRAMAPTNPSR1TP53
SCHEMBL25754841 0.75 POLB (0.45) GAAEDNRAEDNRBMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 PKM 2001/4885GAA 1667/4885EDNRA 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.